Video

Dr. Edington on the Evolving Treatment Paradigm of Melanoma

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Howard D. Edington, MD, director, Cutaneous Oncology Program, Melanoma and Skin Cancer Center, Allegheny Health Network, discusses the evolving treatment paradigm of melanoma.

Medical therapy has undergone tremendous advances in melanoma in recent years, Edington says. The prognosis for stage IV disease, or advanced melanoma, used to be dismal, and now it has become manageable, Edington says.

Despite the progress in treating melanoma, areas of need remain, and the incidence of disease has continued to increase, Edington explains. Recent data suggest that by the year 2040, melanoma will be the second-most commonly diagnosed cancer, trailing only breast cancer, Edington concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center